Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MPIPETrace

Financiado

Cerrado

Clinical performance validation of a novel biomarker for quantitative imaging of...

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease. Coronary Artery Disease (CAD) is the most common form of heart disease and is the leading cause of death in Europe and the Western World. Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) offers the unique poss... ver más

31/03/2019

Synektik S.A.

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

SYNEKTIK SPOLKA AKCYJNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-03-31

PHC-12-2015: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Synektik S.A.

3.69M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SMHEART Smart Cardiac Magnetic Resonance Delivering One-Click and Co... 1M€ Cerrado

DISCHARGE Diagnostic Imaging Strategies for Patients with Stable Chest... 8M€ Cerrado

EUIN2017-86978 DESSARROLLO DE UN BIOMARCADOR PARA LA DETECCION DE LA VULNER... 25K€ Cerrado

DOPPLER-CIP Determining Optimal non invasive Parameters for the Predicti... 3M€ Cerrado

EVINCI-STUDY Evaluation of Integrated Cardiac Imaging for the Detection a... 3M€ Cerrado

iCARE4CVD INDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEAS... 20M€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2016-03-21
Fecha Fin: 2019-03-31

Líder del proyecto

SYNEKTIK SPOLKA AKCYJNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Coronary Artery Disease (CAD) is the most common form of heart disease and is the leading cause of death in Europe and the Western World. Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) offers the unique possibility of measuring and quantifying myocardial blood flow and coronary flow reserve in absolute terms, which serve as a prognostic marker for adverse cardiac events: It can predict the risk of heart attack. PET also offers advantages such as: superior image quality and diagnostic ability, reduction of unnecessary invasive downstream procedures and reduction of patients’ risks due to reduced radiation doses and shorter period of radiation retention. Currently, there is a shortage of available, simple and efficient PET myocardial perfusion imaging agents. Motivated by the growing business opportunity in PET cardiac imaging and the success of completed synthesis and evaluation discovery process, as well as pre-clinical trials and toxicity tests, the objective of this project is Phase 1 and 2 clinical trials of the novel biomarker [11C]-DMDPA for Myocardial Perfusion Imaging using Positron Emission Tomography, and to commercialize it globally. The adoption of Positron Emission Tomography for Myocardial Perfusion Imaging will occur as a result of numerous advantages and the growing abundance and availability of PET scanners in recent and future years. There is compelling evidence that our novel biomarker is addressing a high growth trend in a high volume market of the cardiovascular disease nuclear imaging, and specifically the growing need of non-invasive PET cardiac probes. According to publications, the projected growth rates indicate that PET will outnumber SPECT cardiac procedures by 2020. The willingness to pay has been confirmed during our economic feasibility assessment of the project, by means of consultancy with key stakeholders and negotiations with a number of key players on Diagnostic Partnering deals.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores